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Abstract
About 6 million years ago, our ancestors had experienced a tremendous brain growth, 
widely viewed as a “major adaptive shift” in human evolution. Half of human brain 
composition is fat and 20% of its dry weight is long‐chain polyunsaturated fatty acids 
(LCPUFA). Consequently, improvements in consumption of dietary fat were necessary 
condition for promoting encephalization. Dietary fat quantity and quality have been sub‐
jected to tremendous change over the past 10,000 years with the introduction of industri‐
ally produced trans fatty acids and reduced intakes of ω‐3 fatty acids. The absolute human 
brain size reached its peak of approximately 90,000 years ago and has decreased by 11% 
since 35,000 years ago, most of it (8%) coming in the last 10,000 years. The shortfall in 
consumption of animal foods since the late Paleolithic and mainly consequent shortfall 
in consumption of preformed LCPUFA would be the plausible hypothesis for the brain 
size decreasing. Genetically, we are still adapted to the East African ecosystem on which 
our genome evolved, with some adaptations since the Out‐of‐Africa Diaspora. Dietary 
fat quantity and quality change has caused a conflict with our slowly adapting genome 
and this mismatch is likely to be at the basis of “typically Western” diseases. Many rec‐
ommendations for the intakes of EPA + DHA have been issued, notably for prevention. 
However, the ultimate goal might be to return to the fat quality of our ancient diet on 
which our genes have evolved during the past million years of evolution.
Keywords: human encephalization, LCPUFA sources, dietary transition, LPUFA in 
health, W‐3/W‐6 LCFA and modern diseases, therapeutical W‐3 LCPUFA
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1. Introduction
The evolution of Homo erectus in Africa is widely viewed as a “major adaptive shift” in 
human evolution. Humans share a common ancestor with the chimpanzee and bonobo that 
probably lived in East Africa and, since some 6 million years ago our ancestors had experi‐
enced a tremendous brain growth and assumed an upright position [1].
Half of brain composition is fat, but the central nervous system contains almost a quarter of 
the unesterified cholesterol present in the whole human body and, long‐chain polyunsatu‐
rated fatty acids (LCPUFAs) make up to 20% of brain dry weight, including 6% for arachi‐
donic acid (AA) and 8% for docosahexaenoic acid (DHA) [2].
2. Polyunsaturated fatty acids
LCPUFAs are building blocks of the membrane phospholipids of all cells. Nevertheless, 
LCPUFAs are not only important structural elements of membranes, together with their 
highly potent metabolites (prostaglandins, thromboxanes, leukotrienes, resolvins, and 
(neuro)protectins), LCPUFAs are involved in the functioning of membrane‐bound receptors, 
transporters, ion channels, and enzymes, and also in signal transduction and gene expression.
LCPUFAs are ligands of nuclear transcription factors (PPARS, SREBPs, NF‐kB, and others) [3–6] 
that coordinate expression and repression of key enzymes and proteins participating in interme‐
diary metabolism in glycolysis and “de novo” lipogenesis, thermoregulation, energy partitioning, 
growth and differentiation, hemostasis, and (W‐3/W‐6 ratio) inflammatory responses [7–11].
3. Effect of diet on brain development
The anatomic trends of human evolution (large body sizes, bigger brains, craniofacial, and 
intestinal changes) clearly suggest major energetic and dietary shifts [12–14].
Improvements in dietary quality and the increased consumption of dietary fat appear to have 
been a necessary condition for promoting encephalization in the human lineage [15].
Primitive humans with enlarging brains developed more sophisticated tool technology 
(including the fire cooking) and became more efficient hunter/gatherers and so gained greater 
access to more nutritious and easily digestible foods (e.g., fruits, nuts, and meat) [11].
Consequently, reductions of posterior tooth size (and grinding teeth) and, also the size of the 
face and so, no longer needed the large gastrointestinal tract. Key genetic mutations during 
later hominid evolution were critical to promoting the enhanced lipid metabolism necessary 
for subsisting on diets with greater levels of animal material [16].
In fact, associated with the evolution of our high‐quality diet, humans developed distinct 
molecular pathways for detecting and metabolizing high‐fat foods [17].
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The ability to effectively detect, metabolize, and store fats likely provided tremendous selec‐
tive advantages to our hominid ancestors, allowing them to expand into diverse ecosystems 
around the world [18].
Mammalian brain growth is dependent upon sufficient amounts of two LCPUFAs: DHA and 
AA [19].
It appears that mammals have a limited capacity to synthesize these fatty acids from dietary 
precursors. Because the composition of all mammalian brain tissue is similar with respect 
to these two fatty acids, species with higher levels of encephalization have greater require‐
ments for DHA and AA. Consequently, dietary sources of DHA and AA were likely limiting 
nutrients that constrained the evolution of larger brain size in many mammalian lineages [18].
On average, we consume higher levels of dietary fat than other primates, and much higher 
levels of key LCPUFAs are critical to brain development [20, 21].
Hominins had experienced a tremendous brain growth which coincided with a change from 
a vegetarian to a hunting‐gathering omnivore‐carnivore [22–25].
Greater consumption of animal foods would have increased total dietary fat consumption in 
early Homo, and markedly increased the levels of key fatty acids (AA and DHA) necessary 
for brain development. The available evidence seems to best support a mixed dietary strategy 
in early Homo that involved the consumption of larger amounts of animal foods than with 
the australopithecines. Brain tissue is a rich source of both AA and DHA, whereas liver and 
muscle tissues are good sources of AA and moderate sources of DHA [18].
Dietary fat quantity and quality have been subjected to tremendous change over the past 
10,000 years. Important changes are the introduction of manufactured linoleic acid (LA), 
trans‐fatty acids, and reduced intakes of vegetal‐derived alpha‐linolenic acid (ALA) and fish‐
derived eicosapentaenoic acid (EPA) and DHA, overall leading to a reduced supplying of 
omega‐3 fatty acids [11].
Analysis of changes in brain size in humans over the last 1.8 million years found that encepha‐
lization quotient (EQ) began reaching its peak with the first anatomically modern humans of 
approximately 90,000 years ago and has since remained fairly constant. Most surprisingly, 
however, absolute brain size has decreased by 11% since 35,000 years ago, with most of this 
decrease (8%) coming in just the last 10,000 years. Therefore, a genetic mutation is no more 
likely as an explanation for the decrease in absolute brain size. The most notorious dietary 
change in the last 10,000 years has been the decreased consumption of animal food (roughly 
from 50 to 10%) by the adventure of agriculture, followed by an increased consumption of 
grains. Hence, the most feasible biological hypothesis for the absolute decrease in brain size 
is the reduction of animal food intake with a consequent reduction of preformed long‐chain 
fatty acids. The brain is dependent on the DHA, docosatetraenoic acid (DTA), and AA to sup‐
port its growth during the formative years. These are far more plentiful in animal foods than 
plant. It is possible that the levels of essential fatty acids (EFAs) provided in the prehistoric 
diets were sufficient to support the brain expansion and evolution from prehistoric times to 
the present, and the current low levels of EFA intake (provided by agricultural diets) may 
explain the recent smaller human brain size [26].
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4. Transition of diet and the development of brain disease
Dietary fat quantity and quality change have, together with other man‐made changes in our 
environment, caused a conflict with our slowly adapting genome [11].
In fact, the EFA and other changes in our diet together with an energy intake that does not 
match with our current sedentary lifestyle have caused a conflict with our genome that is 
likely to be at the basis of typically “Western” diseases and their basis on the conflict (mis‐
match) caused by our current sedentary‐energy rich industrialized diet, way of life with our 
ancestrally molded genome. The dietary composition of our ancestors has also become clear 
from our current (patho)physiology: epidemiological data demonstrated a negative associa‐
tion of fish consumption with coronary artery disease (CAD) and (postpartum) depression, 
while landmark trials with ALA and fish oil in CAD, and with EPA in depression and schizo‐
phrenia supported the causality of these relations.
The similarity among diseases currently associated with dietary risk factors adds the notion that 
there is a common insult originated from our changed environment. These effects hit different 
organs and systems varying in genetic susceptibility and life stages, but extremely dependent 
on the doses and exposure time. Low‐grade inflammation might be a strong candidate for this 
common denominator. Low‐grade inflammation can be found in metabolic syndrome and its 
sequelae, some psychiatric and neurodegenerative diseases. The LCPUFA, AA, EPA, and DHA 
are intimately related to the initiation and resolution of inflammatory responses [11].
The current balance between AA and EPA + DHA is disturbed by the dominance of AA, 
which originates from the diet or synthesis from LA. Higher ratio of AA/EPA+DHA might led 
to a pro‐inflammatory condition that may precipitate a hyper‐inflammatory response (“sys‐
temic inflammatory response syndrome‐SIRS”) with collateral damage, scarring and fibrosis 
and the subsequent development of an immune paralysis (“compensatory anti‐inflammatory 
response syndrome‐CARS”) evidenced by debilitated host defense and secondary infection 
susceptibility [27, 28].
The chronic inflammation resulting from the unbalanced AA/EPA + DHA ratio might be cen‐
tral in the pathogenesis of the diseases of the metabolic syndrome and neurodegenerative 
disease, explain the relation between inflammation, depression, and dementia [29].
5. Therapy of modern diseases with polyunsaturated fatty acids
Dietary supplementation of LCFA, especially EPA and DHA, has been used during pregnancy 
or early postnatal life for improvement of fetal and newborn brain development, at primary 
and secondary CAD preventions and psychiatric diseases. Consensus has been reached that 
those in CAD and depression are positive but not in all others. LCPω3 supplements might 
especially be effective in prevention, as suggested by the outcomes of epidemiological studies 
on CAD and prospective studies on Alzheimer's disease, and also from the favorable effects 
of LCPω3 in early disease stages [30].
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It takes 20 years before the human brain obtains its complex adult configuration but the most 
dramatic neurodevelopmental changes occur prenatally and early post‐natal, including a 
major transformation in cortical organization 3–4 months after term and, considerable evi‐
dence indicates that prenatal and neonatal LCPUFA status is associated with neurodevel‐
opmental outcome. Therefore, maternal and neonatal concentrations of DHA and AA are 
associated with improved outcomes in early infancy, and concentrations of DHA are associ‐
ated with favorable neurodevelopmental outcome beyond early infancy [31].
Given the fact that LCPUFA accretion is especially abundant during the third trimester of 
gestation, it suggests that preterm infants would particularly profit from LCPUFA supple‐
mentation. However, studies of LCPUFA supplementation in preterm infants have not shown 
evidence of a positive effect on neurodevelopmental outcome. On the other hand, studies in 
full‐term infants indicated that DHA supplementation promotes neurodevelopmental out‐
come in early infancy but no longer positive effects later on, being virtually absent at school 
age or later. Generally, the literature suggests that LCPUFA supplementation in term infants 
does not affect outcomes beyond the age of 4 months [31].
It is known that up to 45% of the fatty acids of synaptic membranes are EFAs [32].
There is a well‐established positive correlation between depression and coronary artery dis‐
ease. In fact, epidemiological studies in various countries suggest that decreased ω‐3 fatty 
acid consumption correlates with increasing rates of depression and, adequate long‐chain 
polyunsaturated fatty acids, particularly DHA, may reduce the development of depression 
just as ω‐3 polyunsaturated fatty acids may reduce coronary artery disease [33].
Eight database trials that randomly assigned participants to receive ω‐3 PUFAs/fish, with mea‐
sured depressed mood, using human participants, came to the conclusion that trial evidence 
of the effects of ω‐3 PUFAs on depressed mood has increased. However, the considerable het‐
erogeneity of the studies made them difficult to summarize the results. Overall, the available 
evidence supports the benefit of ω‐3 PUFAs in individuals with diagnosed depressive illness 
but no evidence of any benefit in individuals without a diagnosis of depressive illness [34].
The association between fish and meat consumption and risk of dementia in populations in 
developing countries was investigated in low‐ and middle‐ income countries of China, India, 
Cuba, the Dominican Republic, Venezuela, Mexico, and Peru. The found associations of fish and 
meat consumption with dementia risk to populations were consistent with mechanistic data 
on the neuroprotective actions of ω‐3 PUFAs commonly found in fish. However, the inverse 
association between fish and prevalent dementia is unlikely to result from poorer dietary habits 
among demented individuals (reverse causality) because meat consumption was higher in those 
with a diagnosis of dementia. But anyway, the found beneficial effects of fish consumption on 
dementia provide preliminary evidence of the etiological significance of diet in dementia [35].
Given the fact that PUFAs are naturally occurring endogenous substances, present in almost 
all tissues and are essential components of all mammalian cells and can be taken safely for 
long periods of time (from few months to few years) we can conclude that PUFAs, especially 
ω‐3 fatty acids, are useful in the prevention and treatment of Alzheimer’ disease, schizophre‐
nia, and depression [36].
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The pioneering studies in Greenland Eskimos almost 30 years ago suggested that ingestion of 
n‐3 fatty acids conveys protection from cardiovascular diseases [37].
Since then, many interventions have been conducted with LCPUFA, especially EPA and 
DHA, aiming at primary and secondary CAD preventions. From that, in most of the prospec‐
tive cohort studies, n‐3 fatty acids were found to be beneficial [38–43] but there were also 
exceptions with no effect [44, 45].
By comparing people who never or ate fish less than once per month, a meta‐analysis of 11 
prospective studies (11.8 years follow‐up of more than 220 thousand subjects) showed the 
odds ratio for CHD mortality as 0.85 for fish consumption once per week, 0.77 for 2– 4 times/
week, and 0.62 for 5 times/week. The authors calculated that each 20 g/day increase in fish 
intake was associated with a 7% lower risk of coronary heart disease mortality [46].
Many international organizations have made recommendations to increase the intake of EPA 
plus DHA, and these are summarized by the International Society for the Study of Fatty 
Acids and Lipids [47]. In general, these recommendations are for 200 mg/day of EPA plus 
DHA for all adults. The United States has also issued a Dietary Reference Intake for n‐3 fatty 
acids [48].
The 2002 American Heart Association recommendations for dietary intake of n‐3 fatty acids 
recommended: (1) in the absent of documented CHD it is advised to eat fish twice per 
week plus oils and foods rich in ALA (flaxseed, canola, soy, walnuts), this accomplishes 
500 mg/day of n‐3 fatty acids. (2) Individuals already with CHD are advised to eat 1 g/day 
of EPA plus DHA, preferably from oily fish, but could take EPA plus DHA supplements. 
(3) Individuals with hypertriglyceridemia could take 2–4 g/day of EPA plus DHA, under 
prescription care [49].
Several mechanisms have been proposed to explain how EPA plus DHA might beneficially 
influence cardiovascular disease. These include preventing arrhythmias, lowering plasma 
triacylglycerols, decreasing blood pressure, decreasing platelet aggregation, improving vas‐
cular reactivity, and decreasing inflammation. Overall, the therapeutic effect appears to be 
due to suppression of fatal arrhythmias rather than stabilization of atherosclerotic plaques 
[50–60].
Elevated plasma triacylglycerol concentrations have been associated with increased risk of 
coronary heart disease (CHD). Prospective evidence shows that nonfasting plasma triacylg‐
lycerol concentration is a strong and independent predictor of future myocardial infarction 
once elevated postprandial triacylglycerolemia leads to a series of metabolic reactions that 
reduce high‐density lipoprotein (HDL)‐cholesterol concentrations and promote the formation 
of small, dense low‐density lipoprotein (LDL) particles. Metabolism of plasma triacylglycer‐
ols also influences postprandial factor VII activation [61].
EPA and DHA are n‐3 PUFAs in fish oil which are effective hypotriacylglycerolemic agents, 
even when consumed at low doses (1 g n‐3 PUFA/d). Therefore, consumption of n‐3 PUFAs 
provides a realistic option for the optimization of plasma triacylglycerol metabolism [61].
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Omega‐3 fatty acid supplementation provided additional benefits to Lifestyle Modification 
Program (LSMP) in the resolution of metabolic syndrome of free living adults. The fish oil 
group received 3 g of fish oil per day (360 mg of DHA and 540 mg of EPA) (G2, n = 23)) during 
20 weeks. Compared to the control group (only LSMP) the intervened group showed a signifi‐
cant decrease in waist circumference (1.3%) followed by metabolic syndrome reduction (29%) 
mainly due to normalization of blood pressure (33.3%) and triacylglycerol (27.3%). Some the‐
ories have been proposed to explain how omega‐3 reduces triacylglycerol. The strongest evi‐
dence is the reduction in hepatic lipogenesis, reducing hepatic secretion of very low‐density 
lipoprotein (VLDL). Additionally, omega‐3 inhibits certain enzymes involved in the hepatic 
synthesis of triacylglycerol, reducing its plasma level [62].
A significant decrease of plasma oxidative‐stress markers in patients with ulcerative colitis 
was shown when fish oil ω‐3 fatty acids were used in combination with sulfasalazine [63].
Regarding type 2 diabetes mellitus (T2DM), a prospective cohort analysis of men and women 
showed that long‐term dietary intake of long‐chain omega 3 fatty acids does not decrease the 
risk of T2DM. Instead, a modestly but significantly higher incidence of T2DM was associated 
with higher fish and long‐chain omega 3 fatty acid consumption [64].
Doses 3 g/day, EPA plus DHA can improve cardiovascular disease risk factors, including 
decreasing plasma triacylglycerols, blood pressure, platelet aggregation, and inflammation, 
while improving vascular reactivity [50].
By the fact that EFAs and their long‐chain metabolites and other products prevent plate‐
let aggregation, lower blood pressure, reduce LDL‐cholesterol, and ameliorate the adverse 
actions of homocysteine, the EFAs and their metabolites show all the actions expected of the 
“polypill” [65].
The concept of cardiovascular “polypill” was coined [66] by the fact that, when combined, the 
effects of statins, aspirin, and blood pressure lowering drugs reduced the all causes mortality 
in CHD patients.
In conclusion, it is evident that PUFAs, especially an optimal combination of EPA, DHA, 
and possibly, gamma‐linolenic acid (GLA), dihomo‐gamma‐linolenic acid (DGLA), and AA 
show all the qualities of the suggested “polypill”, viz., aspirin‐like action, inhibition of HMG‐
CoA and angiotensin‐converting enzymes (ACEs), and possess diuretic, antihypertensive, 
and beta‐blocker‐like actions. Additionally, given the fact that PUFAs are naturally occur‐
ring endogenous substances, present in almost all tissues and are essential components of 
all mammalian cells and can be taken safely for long periods of time (from few months to 
few years), we can conclude that PUFAs, especially ω‐3 fatty acids, are useful in the preven‐
tion and treatment of Alzheimer’ disease, schizophrenia, and depression [36], suggesting that 
PUFAs have a much wider benefit compared to the “polypill” [65].
Thus, LCPω3 supplements might especially be effective in prevention, as suggested by the 
outcomes of epidemiological studies on CAD and prospective studies on Alzheimer's disease, 
and also from the favorable effects of LCPω3 in early disease stages [30]. Consensus has been 
reached that those interventions in CAD and depression are positive but not in all others.
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6. Future directions
Genetically, we are for the greater part still adapted to the East African ecosystem on which 
our genome evolved, with some adaptations since the Out‐of‐Africa Diaspora. Dietary fat 
quantity and quality change have, together with other man‐made changes in our environ‐
ment, caused a conflict with our slowly adapting genome that is implicated in “typically 
Western” diseases. Fortunately, the majority of Western diseases occur typically after repro‐
ductive age. Rather than reducing our life expectancy, these diseases notably diminish our 
number of years in health.
Many recommendations for the intakes of saturated fat, trans fat, and EPA + DHA have been 
issued, notably for prevention. The ultimate goal might be, however, translate to the culture of 
the current society that our genes had evolved for million years in an entirely different dietary 
composition and lifestyle and therefore we must return to the fat quality of our ancient diet [11].
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